Publications, Pharmaceutical

Using Bioequivalence and Particle Size Distribution to Develop OINDPs

The complexity of demonstrating bioequivalence in complex locally acting orally inhaled and nasal drug products is a barrier to the successful commercialization of generics.

This paper details a study to investigate the performance of a population bioequivalence (PBE) test based on particle size distribution measurements generated by morphologically directed Raman spectroscopy. Simulations of PBE trials were conducted across a range of median particle size and span values. Trial optimization strategies are presented based on the observed data and the general applicability of the approach is underlined. Appropriate trial design can help generic developers to avoid underpowered studies when using complex in vitro techniques to demonstrate bioequivalence.

Download Publication
6 Oct 2020

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

3 Jun 2019

Microbial integrity testing for preservative-free drug formulatio...

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations

Read More
1 Apr 2019

Interview with Guillaume Brouet on Aptar Pharma Services

Publications, Pharmaceutical, Innovation & Insights

Read More
18 Sep 2018

Aptar Pharma provides guidance on FDA regulatory framework for OI...

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
1 Jun 2018

Connected Medicine: Insights from Payers and Other Stakeholders

Publications, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights, Device Innovations

Read More
1 21 22 23 24
Back To Top